Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder
Latest Information Update: 11 Aug 2025
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 30 Jul 2025 According to the Idorsia Pharmaceuticals Media Release, The study is part of a US FDA-approved Pediatric Study Plan and an EU PDCO-approved Paediatric Investigation Plan.
- 30 Jul 2025 According to the Idorsia Pharmaceuticals Media Release, The study is expected to complete enrollment by the end of 2025 with readout expected around mid-2026.
- 07 May 2025 Planned End Date changed from 27 Apr 2025 to 1 Apr 2026.